Potentiation of the Effects of Prismatic Adaptation by Transcranial Direct Current Stimulation (tDCS) : Evaluation of Functional Interest in Negligence Rehabilitation (PRIStiM1)

August 13, 2018 updated by: Hospices Civils de Lyon

Following stroke, over 50% of patients keep severe neurological deficiency whose unilateral neglect, mostly following a right hemispheric lesion. The prismatic adaptation involves to pointing movements toward visual targets wearing prismatic glasses. These prismatic glasses induce a shift to the right visual field for improving symptoms in short term.

Transcranial direct stimulation (tDCS) has been evaluated for different types of deficiency resulting from stroke with encouraging results. The hypothesis of the study is to evaluate the usefulness of brain stimulation as an adjunctive intervention to optimize and increase the rehabilitation of unilateral neglect to long-term.

Thus, the main objective is to evaluate the effectiveness of standard treatment with prismatic adaptation with anodal tDCS or sham tDCS.

Study Overview

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Saint-Genis Laval, France, 69230
        • Hôpital henri Gabriel (Hospices Civils de Lyon)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 76 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Right-handed
  • All subjects must be between the ages of 18-80
  • Patient with unilateral negligence consecutive to a right hemispheric stroke
  • Hospitalized in the Department of Physical Medicine and Rehabilitation (day or week) or external monitoring
  • Ischemic or hemorrhagic stroke with right hemispheric topography - evidenced by a radiological report
  • Diagnosis of negligence evidenced by Behavioural Inattention Test (BIT) : score ≤ 129
  • Stroke >1 month prior to study enrollment

Exclusion Criteria:

  • Degenerative neurological complaint
  • Uncontrolled epilepsy
  • Temporo-spatial disorientation
  • Language disorders or psychiatric disorders preventing understanding instructions
  • History of prior stroke, multiple stroke
  • Medical condition not stabilized
  • Pregnancy
  • Implanted material (pacemaker, defibrillator, cochlear implant, surgical clips, metal object)
  • Intra-cranial material
  • Unweaned alcoholism

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Arm A Anodal tDCS and prismatic adaptation
anodal tDCS over the primary motor cortex : stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
Anodal tDCS over the primary motor cortex. Stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
Placebo Comparator: Arm B: control
Prismatic adaptation with placebo stimulation
electrode of sham tDCS over the primary motor cortex during 20 minutes (5 consecutive sessions during one week).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Behavioural Inattention Test (BIT)
Time Frame: Change in BIT score between the baseline sessions average and score measured at week 11
assessed at two baseline sessions before intervention (inclusion and week 3), and after the therapeutic intervention week (week 5), 2 weeks (week 7), 6 weeks (week 11) and 15 weeks (week 20) following the inclusion.
Change in BIT score between the baseline sessions average and score measured at week 11

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Negligence Battery Test (BTN)
Time Frame: before intervention (week 1 and week 3), and then again following the intervention (week 5), 2 weeks (week 7), 6 weeks (week 11) and 15 weeks (week 20)
Change in BTN scores between baseline measures before the therapeutic intervention week and scores obtained during each follow-up sessions
before intervention (week 1 and week 3), and then again following the intervention (week 5), 2 weeks (week 7), 6 weeks (week 11) and 15 weeks (week 20)
Functional independence scale (MIF)
Time Frame: before intervention (week 1 and week 3), and then again following the intervention (week 5), 2 weeks (week 7), 6 weeks (week 11) and 15 weeks (week 20)
Change in MIF scores between baseline measures before the therapeutic intervention week and scores obtained during each follow-up sessions
before intervention (week 1 and week 3), and then again following the intervention (week 5), 2 weeks (week 7), 6 weeks (week 11) and 15 weeks (week 20)
Catherine Bergego scale (ECB)
Time Frame: baseline session before intervention (week 1 and week 3), and then again following the intervention (week 5), 2 weeks (week 7), 6 weeks (week 11) and 15 weeks (week 20)
Change in ECB scores between baseline measures before the therapeutic intervention week and scores obtained during each follow-up sessions
baseline session before intervention (week 1 and week 3), and then again following the intervention (week 5), 2 weeks (week 7), 6 weeks (week 11) and 15 weeks (week 20)
Jamar
Time Frame: baseline session before intervention (week 1 and week 3), and then again following the intervention (week 5), 2 weeks (week 7), 6 weeks (week 11) and 15 weeks (week 20)
Change in Jamar scores between baseline measures before the therapeutic intervention week and scores obtained during each follow-up sessions
baseline session before intervention (week 1 and week 3), and then again following the intervention (week 5), 2 weeks (week 7), 6 weeks (week 11) and 15 weeks (week 20)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sophie JACQUIN-COURTOIS, MD-PhD, Hospices Civils de Lyon

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 26, 2014

Primary Completion (Actual)

May 25, 2018

Study Completion (Actual)

May 25, 2018

Study Registration Dates

First Submitted

August 8, 2014

First Submitted That Met QC Criteria

August 8, 2014

First Posted (Estimate)

August 11, 2014

Study Record Updates

Last Update Posted (Actual)

August 14, 2018

Last Update Submitted That Met QC Criteria

August 13, 2018

Last Verified

August 1, 2018

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neurologic Neglect Syndrome

Clinical Trials on transcranial direct current stimulation (tDCS)

Subscribe